Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.

[1]  I. Pavord,et al.  A new perspective on concepts of asthma severity and control , 2008, European Respiratory Journal.

[2]  D. Nash,et al.  In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. , 2008, Managed care.

[3]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[4]  A. Didier,et al.  Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. , 2008, Respiratory medicine.

[5]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[6]  W. Busse,et al.  Severe asthma in adults: what are the important questions? , 2007, The Journal of allergy and clinical immunology.

[7]  J. Bousquet,et al.  Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma , 2007, Allergy.

[8]  H. Sitter,et al.  Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma , 2006, Pneumologie.

[9]  W. Moore,et al.  Severe asthma: an overview. , 2006, The Journal of allergy and clinical immunology.

[10]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[11]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[12]  T. Casale,et al.  Omalizumab is well tolerated in adolescent/adult patients (≥12 Years) with moderate-to-severe persistent asthma , 2005 .

[13]  R. Buhl.  Anti-IgE antibodies for the treatment of asthma , 2005, Current opinion in pulmonary medicine.

[14]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[15]  E. Chilvers,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma , 2004, Allergy.

[16]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[17]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  G. Marshall,et al.  Unanswered questions on omalizumab (Xolair) patient selection and follow-up. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  W. Lumry,et al.  Omalizumab is effective in the long-term control of severe allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[21]  E. Matsui,et al.  OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA , 2003 .

[22]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[23]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[24]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[25]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .